[go: up one dir, main page]

NO20074391L - CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter - Google Patents

CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter

Info

Publication number
NO20074391L
NO20074391L NO20074391A NO20074391A NO20074391L NO 20074391 L NO20074391 L NO 20074391L NO 20074391 A NO20074391 A NO 20074391A NO 20074391 A NO20074391 A NO 20074391A NO 20074391 L NO20074391 L NO 20074391L
Authority
NO
Norway
Prior art keywords
cis
cancer drugs
compounds
imidazolines
triaryl
Prior art date
Application number
NO20074391A
Other languages
English (en)
Inventor
Stephen E Webber
Binh Thanh Vu
Gregory Jay Haley
Klaus B Simonsen
Nader Fotouhi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20074391L publication Critical patent/NO20074391L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er presentert forbindelser med formel (I) eller farmasøytisk akseptable salter derav, hvor Yi,Y,Xi,X,Xog R er som beskrevet i denne søknaden. Disse forbindelser er antatt å hemme MDM2-p53 interaksjon og som sådanne vil forbindelsene ha anti-hyperproliferativ cellulær aktivitet.
NO20074391A 2005-03-16 2007-08-29 CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter NO20074391L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66251605P 2005-03-16 2005-03-16
PCT/EP2006/002282 WO2006097261A1 (en) 2005-03-16 2006-03-13 Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments

Publications (1)

Publication Number Publication Date
NO20074391L true NO20074391L (no) 2007-12-11

Family

ID=36572145

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074391A NO20074391L (no) 2005-03-16 2007-08-29 CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter

Country Status (16)

Country Link
US (1) US7579368B2 (no)
EP (1) EP1861376A1 (no)
JP (1) JP4955646B2 (no)
KR (2) KR20100031783A (no)
CN (1) CN101155784A (no)
AR (1) AR053446A1 (no)
AU (1) AU2006224765B2 (no)
BR (1) BRPI0607445A2 (no)
CA (1) CA2599476A1 (no)
IL (1) IL185381A0 (no)
MX (1) MX2007011151A (no)
NO (1) NO20074391L (no)
RU (1) RU2411238C2 (no)
TW (1) TWI314552B (no)
WO (1) WO2006097261A1 (no)
ZA (1) ZA200707653B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672565A1 (en) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Imidazothiazole derivatives
EP2298778A4 (en) 2008-06-12 2011-10-05 Daiichi Sankyo Co Ltd IMIDAZOTHIAZOLE DERIVATE HAVING A CYCLIC STRUCTURE OF 4,7-DIAZASPIRO®2.5OCITANE
CN101906085B (zh) * 2009-06-04 2013-12-11 天津药物研究院 治疗心脑血管疾病的化合物、组合物、制备方法及用途
MX2012002420A (es) * 2009-08-26 2012-06-27 Novartis Ag Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4.
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9266860B2 (en) 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
JP2015531790A (ja) * 2012-09-19 2015-11-05 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ アセチレン架橋したリンカー、及びこれらから製造された金属−有機フレームワーク（ＭＯＦｓ）
WO2014082889A1 (en) * 2012-11-28 2014-06-05 F. Hoffmann-La Roche Ag Novel imidazolines as dual inhibitors of mdm2 and mdmx
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
WO2015019616A1 (en) 2013-08-07 2015-02-12 Toyo Gosei Co., Ltd. Reagent for enhancing generation of chemical species
CN104418867B (zh) * 2013-08-26 2016-12-28 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
WO2015184383A1 (en) * 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
CN109415336B (zh) 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
US11207312B2 (en) 2017-07-17 2021-12-28 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors and methods of use thereof
CA3107168A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CA3112591A1 (en) 2018-10-08 2020-04-16 The Regents Of The University Of Michigan Small molecule mdm2 protein degraders
IL296451A (en) 2020-03-19 2022-11-01 Kymera Therapeutics Inc Mdm2 degraders and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301717T3 (es) * 2001-12-18 2008-07-01 F. Hoffmann-La Roche Ag Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores.
US7425638B2 (en) * 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
CN100465163C (zh) * 2003-06-17 2009-03-04 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三芳基-咪唑啉类化合物
ES2314660T3 (es) 2004-05-18 2009-03-16 F. Hoffmann-La Roche Ag Nuevas cis-imidazolinas.
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines

Also Published As

Publication number Publication date
JP4955646B2 (ja) 2012-06-20
IL185381A0 (en) 2008-02-09
JP2008533073A (ja) 2008-08-21
RU2411238C2 (ru) 2011-02-10
KR101139263B1 (ko) 2012-05-16
CN101155784A (zh) 2008-04-02
AR053446A1 (es) 2007-05-09
TW200700393A (en) 2007-01-01
KR20100031783A (ko) 2010-03-24
CA2599476A1 (en) 2006-09-21
US7579368B2 (en) 2009-08-25
AU2006224765A1 (en) 2006-09-21
KR20070107129A (ko) 2007-11-06
WO2006097261A1 (en) 2006-09-21
TWI314552B (en) 2009-09-11
MX2007011151A (es) 2007-10-17
US20060211693A1 (en) 2006-09-21
BRPI0607445A2 (pt) 2009-09-01
ZA200707653B (en) 2013-02-27
EP1861376A1 (en) 2007-12-05
AU2006224765B2 (en) 2012-02-09
RU2007137987A (ru) 2009-04-27

Similar Documents

Publication Publication Date Title
NO20074391L (no) CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20071593L (no) Pyrimidinderivater
TW200615266A (en) Organic compounds
NO20091394L (no) Pyridin-4-yl-derivater som immunmodulerende midler
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
ATE389635T1 (de) Pharmazeutisch wirksame piperidinderivate
UA94065C2 (en) Dihydropseudoerythromycin derivatives
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20070176L (no) Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20076648L (no) Novel thiophene derivatives
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
NO20074441L (no) 1-benzylindol-2-karboksamidderivater
NO20070089L (no) DPP-IV inhibitorer
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20070445L (no) Pyrimidinderivater.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application